Neurocrine Biosciences, Inc. $NBIX Shares Bought by Barclays PLC

Barclays PLC lifted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 12.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 303,978 shares of the company’s stock after buying an additional 32,588 shares during the period. Barclays PLC owned about 0.30% of Neurocrine Biosciences worth $42,672,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in the stock. Arrowstreet Capital Limited Partnership boosted its holdings in Neurocrine Biosciences by 87.9% during the second quarter. Arrowstreet Capital Limited Partnership now owns 125,162 shares of the company’s stock worth $15,732,000 after buying an additional 58,562 shares in the last quarter. Saturn V Capital Management LP purchased a new position in Neurocrine Biosciences in the second quarter valued at about $7,313,000. Capital Fund Management S.A. lifted its position in shares of Neurocrine Biosciences by 15.9% during the 2nd quarter. Capital Fund Management S.A. now owns 203,628 shares of the company’s stock valued at $25,594,000 after acquiring an additional 27,987 shares during the period. Rhenman & Partners Asset Management AB lifted its position in shares of Neurocrine Biosciences by 66.1% during the 2nd quarter. Rhenman & Partners Asset Management AB now owns 149,217 shares of the company’s stock valued at $18,755,000 after acquiring an additional 59,400 shares during the period. Finally, Robeco Institutional Asset Management B.V. boosted its stake in shares of Neurocrine Biosciences by 86.7% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 28,185 shares of the company’s stock worth $3,957,000 after acquiring an additional 13,087 shares in the last quarter. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Neurocrine Biosciences Stock Performance

Shares of NBIX opened at $129.93 on Tuesday. The company’s 50 day simple moving average is $134.04 and its 200 day simple moving average is $140.47. The company has a market capitalization of $13.04 billion, a price-to-earnings ratio of 27.88, a PEG ratio of 0.67 and a beta of 0.32. Neurocrine Biosciences, Inc. has a 1 year low of $84.23 and a 1 year high of $160.18.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Wednesday, February 11th. The company reported $1.88 earnings per share for the quarter, missing analysts’ consensus estimates of $2.36 by ($0.48). The business had revenue of $805.50 million for the quarter, compared to analysts’ expectations of $804.21 million. Neurocrine Biosciences had a return on equity of 16.48% and a net margin of 16.73%.The company’s revenue for the quarter was up 28.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.69 EPS. Equities analysts expect that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Royal Bank Of Canada lowered their target price on Neurocrine Biosciences from $180.00 to $177.00 and set an “outperform” rating on the stock in a report on Thursday, February 12th. Wall Street Zen lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, February 16th. BMO Capital Markets lowered their target price on Neurocrine Biosciences from $147.00 to $140.00 and set a “market perform” rating on the stock in a report on Thursday, February 12th. Morgan Stanley reissued an “equal weight” rating and set a $175.00 price target (up from $173.00) on shares of Neurocrine Biosciences in a research report on Thursday, January 8th. Finally, Needham & Company LLC cut their price target on Neurocrine Biosciences from $187.00 to $185.00 and set a “buy” rating for the company in a report on Thursday, February 12th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $175.05.

Insider Transactions at Neurocrine Biosciences

In related news, Director Leslie V. Norwalk sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $152.23, for a total value of $761,150.00. Following the sale, the director directly owned 7,429 shares of the company’s stock, valued at approximately $1,130,916.67. This trade represents a 40.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Kyle Gano sold 36,400 shares of Neurocrine Biosciences stock in a transaction on Friday, January 16th. The shares were sold at an average price of $132.70, for a total transaction of $4,830,280.00. Following the completion of the transaction, the chief executive officer owned 140,407 shares in the company, valued at approximately $18,632,008.90. This trade represents a 20.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 42,590 shares of company stock valued at $5,775,987. Corporate insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.